Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Johanna C. Bendell, Chloe Evelyn Atreya, Thierry André, Josep Tabernero, Michael S. Gordon, Rene Bernards, Eric Van Cutsem, Sabine Tejpar, Roger Sidhu, William Y. Go, Alicia Allred, Monica Motwani, Benjamin B. Suttle, Yuehui Wu, Axel Hoos, Keith W. Orford, Ryan Bruce Corcoran, Jan HM Schellens
Institutions: Sarah Cannon, University of California, San Francisco, Hôpital Saint-Antoine, Vall d'Hebron Hospital Universitari, Pinnacle Oncology Hematology, The Netherlands Cancer Institute, Universitair Ziekenhuis Leuven, KU Leuven, Amgen (United States), GlaxoSmithKline (United States), Massachusetts General Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2472619494